Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FBRX - Forte Biosciences, Inc.

IEX Last Trade
16
-0.760   -4.750%

Share volume: 72,645
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.38%

PREVIOUS CLOSE
CHG
CHG%
$16.76
-1.78
-0.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
11%
Profitability 8%
Dept financing 7%
Liquidity 58%
Performance 3%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-10.01%
1 Month
-15.61%
3 Months
236.84%
6 Months
2,757.14%
1 Year
2,160.84%
2 Year
1,453.40%
Key data
Stock price
$16.00
P/E Ratio 
0.00
DAY RANGE
$14.88 - $19.30
EPS 
-$13.46
52 WEEK RANGE
$0.33 - $28.68
52 WEEK CHANGE
$2,160.84
MARKET CAP 
8.162 M
YIELD 
N/A
SHARES OUTSTANDING 
36.504 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
-0.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$53,123
AVERAGE 30 VOLUME 
$58,697
Company detail
CEO: Paul A. Wagner
Region: US
Website: fortebiorx.com
Employees: 5
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Forte Biosciences is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Recent news